Congresos y publicaciones

Alternative dosing regimens of tislelizumab proposed using modeling and simulation First-in-human, phase 1a, dose escalation study of BGB-B167, a CEA x 4-1BB bispecific antibody, as monotherapy or combined with tislelizumab (anti-PD-1), in patients with selected advanced or metastatic solid tumors First-line (1L) tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 Japanese subgroup analysis with longer follow-up Impact of tislelizumab + chemotherapy versus placebo + chemotherapy on patient-reported symptoms and disease progression by programmed death-ligand 1 expression in gastroesophageal adenocarcinoma: a post hoc analysis of the RATIONALE-305 trial Impact of tislelizumab + chemotherapy versus placebo + chemotherapy on patient-reported symptoms and overall survival (OS) by programmed death-ligand 1 (PD-L1) expression in advanced or metastatic esophageal squamous cell carcinoma (ESCC): A post hoc analysis of the RATIONALE-306 trial

First-in-human phase 1a, dose-escalation study of BGB-43395 (CDK4-selective inhibitor) as monotherapy and in combination with fulvestrant or letrozole in patients with metastatic HR+/HER2− breast cancer and other advanced solid tumors Preclinical characterization of BGB-43395, a potential best-in-class CDK4 selective inhibitor with potent pharmacodynamic and anti-tumor activity in HR+HER2- breast cancer models Trial in progress: A first-in-human phase 1a/b, dose-escalation/expansion study of BG-68501/ETX-197 (CDK2 inhibitor) as monotherapy or in combination with fulvestrant for patients with HR+/HER2− breast cancer and other advanced solid tumors Trial in progress: First-in-human phase 1a/1b, dose-escalation/expansion study of BGB-43395 (CDK4 selective inhibitor) as monotherapy or combination therapy in Chinese patients with metastatic HR+/HER2− breast cancer and other advanced solid tumors

First-in-human phase 1a, dose-escalation study of BGB-43395 (CDK4-selective inhibitor) as monotherapy and in combination with fulvestrant or letrozole in patients with metastatic HR+/HER2− breast cancer and other advanced solid tumors Preclinical characterization of BGB-43395, a potential best-in-class CDK4 selective inhibitor with potent pharmacodynamic and anti-tumor activity in HR+HER2- breast cancer models Trial in progress: A first-in-human phase 1a/b, dose-escalation/expansion study of BG-68501/ETX-197 (CDK2 inhibitor) as monotherapy or in combination with fulvestrant for patients with HR+/HER2− breast cancer and other advanced solid tumors Trial in progress: First-in-human phase 1a/1b, dose-escalation/expansion study of BGB-43395 (CDK4 selective inhibitor) as monotherapy or combination therapy in Chinese patients with metastatic HR+/HER2− breast cancer and other advanced solid tumors

Final analysis of a phase 1 study of zanubrutinib plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory Waldenstrom macroglobulinemia: results from the phase 1 CaDAnCe-101 study Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: results from the phase 1 CaDAnCe-101 study Sonrotoclax and zanubrutinib as frontline treatment for CLL demonstrates high MRD clearance rates with good tolerability: data from an ongoing phase 1/1b study BGB-11417-101

BGB-11417-203, an ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenstrom macroglobulinemia CELESTIAL-TNCLL: an ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naive CLL Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed/refractory follicular lymphoma: growth modulation index analysis from ROSEWOOD study Deep and sustained responses in patients with CLL treated with zanubrutinib or zanubrutinib + obinutuzumab in phase 1/2 AU-003 and phase 1b GA-101 studies: a report from the zanubrutinib extension study Evaluating reasons for differences in real-world clinical outcomes among patients with relapsed/refractory mantle cell lymphoma on covalent BTK inhibitors Impact of novel therapies on real-world clinical outcomes of patients with relapsed/refractory mantle cell lymphoma by race/ethnicity and TP53 mutation status Long-term clinical outcomes in patients with Waldenstrom macroglobulinemia who received zanubrutinib in the phase 3 ASPEN study: a report from the zanubrutinib extension study Long-term impact of dose interruptions of Bruton tyrosine kinase inhibitors on change in IgM levels and clinical outcomes in Waldenström macroglobulinemia Multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in treatment-naive chronic lymphocytic leukemia: 5-year follow up, retreatment outcomes, and impact of MRD kinetics (ΔMRD400) Patient medication preferences in follicular lymphoma in the United States: a discrete choice experiment Preliminary efficacy and safety of the Bruton tyrosine kinsae degrader BGB-16673 in patients with relapsed or refractory indolent NHL: results from the phase 1 CaDAnCe-101 study Prospective patient preference study for Bruton tyrosine kinase inhibitor treatment attributes and factors affecting patient shared decision-making in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States Real-world Bruton tyrosine kinase inhibitor utilization and clinical outcomes among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma Sustained superiority of zanubrutinib vs bendamustine + rituximab in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: 5-year follow-up of cohort 1 from the SEQUOIA study Zanubrutinib is well tolerated and effective in acalabrutinib-intolerant patients with B-cell malignancies iPSC-derived CAR-γδT with novel combinatorial KO demonstrated extended longevity and profound anti-tumor efficacy without cytokine support in preclinical studies

BGB-11417-203, an ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia BGB-16673, a selective BTK degrader, exhibits deeper inhibition of cancer cell signaling pathways and better efficacy in MCL models CELESTIAL-TNCLL: an ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naive CLL Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed/refractory follicular lymphoma: growth modulation index analysis from ROSEWOOD study Deep and sustained responses in patients with CLL treated with zanubrutinib or zanubrutinib + obinutuzumab in phase 1/2 AU-003 and phase 1b GA-101 studies: a report from the zanubrutinib extension study Discovery of the unique GMP-Grade iPSC clones that give rise to functional, high purity, matured CD8 αβT or γδT with exponential expansion capacity Evaluating reasons for differences in real-world (RW) clinical outcomes among patients with relapsed/refractory mantle cell lymphoma (R/R MCL) on covalent BTK inhibitors (cBTKis) Final analysis of a phase 1 study of zanubrutinib plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma Impact of novel therapies (NTs) on real-world (RW) clinical outcomes of patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) by race/ethnicity and TP53 mutation status Long-term clinical outcomes in patients with Waldenström macroglobulinemia (WM) who received zanubrutinib in the phase 3 ASPEN study: a report from the zanubrutinib extension study Long-term impact of dose interruptions (DIs) of Bruton tyrosine kinase inhibitors (BTKis) on change in IgM levels and clinical outcomes in Waldenström macroglobulinemia (WM) Multicenter Phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in treatment-naïve chronic lymphocytic leukemia: 5-year follow up, retreatment outcomes, and impact of MRD kinetics (ΔMRD400) Patient medication preferences in follicular lymphoma (FL) in the United States (USA): a discrete choice experiment (DCE) Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory (R/R) indolent NHL: results from the phase 1 CaDAnCe-101 study Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory Waldenström macroglobulinemia: results from the phase 1 CaDAnCe-101 study Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: results from the phase 1 CaDAnCe-101 study Prospective patient preference study for Bruton tyrosine kinase inhibitor (BTKi) treatment attributes and factors affecting patient shared decision-making chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in the United States (USA) Real-world Bruton tyrosine kinase inhibitor (BTKi) utilization and clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) Sonrotoclax and zanubrutinib as frontline treatment for CLL demonstrates high MRD clearance rates with good tolerability: data from an ongoing phase 1/1b study BGB-11417-101 Sustained superiority of zanubrutinib vs bendamustine + rituximab in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL): 5-year follow-up of cohort 1 from the SEQUOIA study Treatment with zanubrutinib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were previously treated with another Bruton tyrosine kinase inhibitor in a US community oncology setting Zanubrutinib is well tolerated and effective in acalabrutinib-intolerant patients with B-cell malignancies iPSC-derived CAR-γδT with SOCS1/CISH/BIM/FAS combinatorial KO demonstrated extended longevity and profound anti-tumor efficacy without cytokine support in preclinical studies

Asia subgroup overall survival and long-term follow-up results of the phase 2b HERIZON-BTC-01 study: Zanidatamab in previously treated human epidermal growth factor receptor 2 (HER2)-amplified biliary tract cancer (BTC) Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as first-line (1L) treatment for recurrent or metastatic nasopharyngeal cancer (NPC): 3-year follow-up from the RATIONALE-309 study Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Patient reported outcomes (PRO) in the Asian subgroup of the RATIONALE-305 study

Characteristics and treatment patterns of patients diagnosed with nasopharyngeal carcinoma in Indonesia: A descriptive study using the national health insurance database Direct medical costs of nasopharyngeal carcinoma in Indonesia: A healthcare payer perspective RATIONALE-304 long-term outcomes: First-line tislelizumab (tis) + chemotherapy (chemo) vs chemo for locally advanced or metastatic nonsquamous (NSQ) NSCLC

Asia subgroup overall survival and long-term follow-up results of the phase 2b HERIZON-BTC-01 study: Zanidatamab in previously treated human epidermal growth factor receptor 2 (HER2)-amplified biliary tract cancer (BTC) Characteristics and treatment patterns of patients diagnosed with nasopharyngeal carcinoma in indonesia: A descriptive study using the national health insurance database Direct medical costs of nasopharyngeal carcinoma in Indonesia: A healthcare payer perspective RATIONALE-304 long-term outcomes: First-line tislelizumab (tis) + chemotherapy (chemo) vs chemo for locally advanced or metastatic nonsquamous (NSQ) NSCLC Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as first-line (1L) treatment for recurrent or metastatic nasopharyngeal cancer (NPC): 3-year follow-up from the RATIONALE-309 study Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Patient reported outcomes (PRO) in the Asian subgroup of the RATIONALE-305 study

Cost-effectiveness of zanubrutinib + obinutuzumab for treatment of relapsed or refractory follicular lymphoma in the United States Economic evaluatio of tislelizumab for the treatment of second-line esophageal squamous cell carcinoma: a lifetime partition survival model Epidemiological disparities and risk factors of esophageal cancer in Türkiye: a systematic review Examining the impact of tislelizumab added to chemotherapy on health-related quality of life (HRQoL) outcomes in patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC): the RATIONALE-306 study Systematic literature reivew (SLR) of randomized controlled trials (RCTs) of treatments for first-line (1L) gastric cancer/gastroesophageal junction adenocarcinoma (GC/GEJ) in adult patients Systematic literature review (SLR) of disease burden related to first-line (1L ) unresectable, locally advanced, or metastatic esophageal squamous cell carcinoma (ESCC) The importance of assessment design when caputuring reasons for therapeutic change in cancer care

Cost-effectiveness of zanubrutinib + obinutuzumab for treatment of relapsed or refractory follicular lymphoma in the United States Economic evaluation of tislelizumab for the treatment of second-line oesophageal squamous cell carcinoma: a lifetime partition survival model Epidemiological disparities and risk factors of esophageal cancer in Türkiye: A systematic review Examining the impact of tislelizumab added to chemotherapy on health‑related quality of life (HRQoL) outcomes in patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC): the RATIONALE-306 study Systematic literature review (SLR) of disease burden related to first-line (1L) unresectable, locally advanced, or metastatic esophageal squamous cell carcinoma (ESCC) Systematic literature review (SLR) of randomized controlled trials (RCTs) of treatments for first-line (1L) gastric cancer/gastroesophageal junction adenocarcinoma (GC/GEJ) in adult patients The importance of assessment design when capturing reasons for therapeutic change in cancer care

Concordance among three programmed death-ligand 1 (PD-L1) scoring methods and their association with clinical outcomes of tislelizumab (TIS) monotherapy in esophageal squamous cell carcinoma (ESCC) Global, randomized, phase 3 study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): minimum 3-year survival follow-up Pathological response to neoadjuvant tislelizumab (TIS) plus platinum-doublet (PtDb) chemotherapy (CT) in resectable stage II-IIIa NSCLC patients (pts) in the phase 3 (Ph3) RATIONALE-315 trial Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): final analysis (FA) results of the RATIONALE-305 study Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) + chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): health-related quality of life (HRQoL) outcomes in RATIONALE-305 Tislelizumab + chemotherapy (CT) vs placebo + CT as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: RATIONALE-305 European/North American patient subgroup

Concordance among three programmed death-ligand 1 (PD-L1) scoring methods and their association with clinical outcomes of tislelizumab (TIS) monotherapy in esophageal squamous cell carcinoma (ESCC) Global, randomized, phase 3 study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): minimum 3-year survival follow-up Pathological response to neoadjuvant tislelizumab (TIS) plus platinum-doublet (PtDb) chemotherapy (CT) in resectable stage II-IIIa NSCLC patients (pts) in the phase 3 (Ph3) RATIONALE-315 trial Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): final analysis (FA) results of the RATIONALE-305 study Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) + chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): health-related quality of life (HRQoL) outcomes in RATIONALE-305 Tislelizumab + chemotherapy (CT) vs placebo + CT as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: RATIONALE-305 European/North American patient subgroup